Here are the 10-Q quarterly reports from Amicus Therapeutics, Inc (FOLD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FOLD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FOLD filings page.
Amicus Therapeutics reported stronger Q3 2025 results. Net product sales were $169.1 million, up from $141.5 million. The company posted net income of $17.3 million versus a loss a year ago. For the first nine months, sales reached $449.0 million and net loss narrowed to $28.8 million.
Galafold generated $371.5 million in year-to-date revenue, while Pombiliti + Opfolda contributed $77.5 million. Gross profit for the first nine months was $402.6 million. Operating cash flow was $16.9 million for the period. Cash, cash equivalents, and marketable securities totaled $263.8 million as of September 30, 2025.
Long-term debt carrying value was $392.0 million on a $400.0 million senior secured term loan due 2029. Inventory increased to $177.9 million to support commercial growth. The company recorded a $30 million upfront R&D expense tied to a U.S. license for Dimerix’s DMX-200. Shares outstanding were 308,533,548 as of October 24, 2025.